Literature DB >> 22717697

Therapeutic efficacy of silibinin on human neuroblastoma cells: Akt and NF-κB expressions may play an important role in silibinin-induced response.

Meysam Yousefi1, Seyed H Ghaffari, Bahram M Soltani, Shahriar Nafissi, Majid Momeny, Ali Zekri, Mehrdad Behmanesh, Kamran Alimoghaddam, Ardeshir Ghavamzadeh.   

Abstract

Neuroblastoma is the most common solid tumor in children. Current therapy modalities have resulted in little amelioration in the cure rate of neuroblsatoma and therefore, outlining biologically based therapies for neuroblastoma remains of main priority. This study was carried out to appraise the impeding effects of silibinin, a potent anti-cancer agent, on two different neuroblastoma cell lines, stromal SK-N-MC and neuroblastic SK-N-BE(2) cells. The microculture tetrazolium assay, gelatin zymography, colony formation assay, cell cycle distribution survey, apoptosis assay, and quantitative real-time reverse transcription-PCR were applied to evaluate the effects of silibinin on metabolic activity, gelatinolytic activity of MMP-2 and MMP-9, surviving potential, cell cycle, apoptosis, and expression pattern of the genes involved in cell survival and invasion of the two neuroblastoma cell lines. Treatment for 48 h inhibited metabolic activity and clonogenic potential of SK-N-MC cells in a dose-dependent manner. Silibinin also inhibited transcriptional levels of MMP-2, MMP-9, and uPAR, as markers of cell invasion, in SK-N-MC cells. Higher concentration of silibinin (75, 100 μM) suppressed enzymatic activity of MMP-2 in this cell line. No change in apoptosis and cell cycle was observed in neither of the cells after treatment with silibinin. On the other hand, silibinin highly decreased mRNA expression of Akt, and NF-κB1 and its regulators, IKK1 and IKK2 in SK-N-MC cell line. Comparison of transcriptional expression of Akt, and NF-κB1 in untreated stromal and neuroblastic cell lines shows that their basal transcriptional levels are much higher in SK-N-BE(2) cell line than that in SK-N-MC cells. It seems that SK-N-BE(2) cell line probably resists to silibinin through higher expression of Akt and probably NF-κB1. Collectively, our results demonstrated that silibinin highly inhibits the proliferative potentials of SK-N-MC cell line, whilst it had less inhibitory effect on SK-N-BE(2) cell line. Our results suggest that suppression of SK-N-MC cell line by silibinin may be through inhibition of Akt-mediated NF-κB1.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22717697     DOI: 10.1007/s11064-012-0827-9

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  46 in total

1.  Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome.

Authors:  T Ara; M Fukuzawa; T Kusafuka; Y Komoto; T Oue; M Inoue; A Okada
Journal:  J Pediatr Surg       Date:  1998-08       Impact factor: 2.545

2.  Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma.

Authors:  Shoichi Nagai; Kazuo Washiyama; Masanori Kurimoto; Akira Takaku; Shunro Endo; Toshiro Kumanishi
Journal:  J Neurosurg       Date:  2002-05       Impact factor: 5.115

3.  Induction of NF-kappaB by the Akt/PKB kinase.

Authors:  L P Kane; V S Shapiro; D Stokoe; A Weiss
Journal:  Curr Biol       Date:  1999-06-03       Impact factor: 10.834

4.  Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor.

Authors:  R Yao; G M Cooper
Journal:  Science       Date:  1995-03-31       Impact factor: 47.728

5.  Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer.

Authors:  Eiji Oki; Hideo Baba; Eriko Tokunaga; Toshihiko Nakamura; Naoyuki Ueda; Motonori Futatsugi; Kohjiro Mashino; Manabu Yamamoto; Masahiko Ikebe; Yoshihiro Kakeji; Yoshihiko Maehara
Journal:  Int J Cancer       Date:  2005-11-10       Impact factor: 7.396

6.  Synergistic effects of arsenic trioxide and silibinin on apoptosis and invasion in human glioblastoma U87MG cell line.

Authors:  Majid Zaki Dizaji; Mohsen Malehmir; Ardeshir Ghavamzadeh; Kamran Alimoghaddam; Seyed H Ghaffari
Journal:  Neurochem Res       Date:  2011-10-04       Impact factor: 3.996

7.  The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

Authors:  Arnab Chakravarti; Gary Zhai; Yoshiyuki Suzuki; Sormeh Sarkesh; Peter M Black; Alona Muzikansky; Jay S Loeffler
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

8.  Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines.

Authors:  J S Isaacs; R Hardman; T A Carman; J C Barrett; B E Weissman
Journal:  Cell Growth Differ       Date:  1998-07

9.  HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

Authors:  Christiane Knuefermann; Yang Lu; Bolin Liu; Weidong Jin; Ke Liang; Ling Wu; Mathias Schmidt; Gordon B Mills; John Mendelsohn; Zhen Fan
Journal:  Oncogene       Date:  2003-05-22       Impact factor: 9.867

10.  Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.

Authors:  M R Abedini; E J Muller; R Bergeron; D A Gray; B K Tsang
Journal:  Oncogene       Date:  2009-10-05       Impact factor: 9.867

View more
  7 in total

1.  Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.

Authors:  S DebRoy; N Hiraga; M Imamura; C N Hayes; S Akamatsu; L Canini; A S Perelson; R T Pohl; S Persiani; S L Uprichard; C Tateno; H Dahari; K Chayama
Journal:  J Viral Hepat       Date:  2016-06-08       Impact factor: 3.728

2.  Cytotoxic and toxicogenomic effects of silibinin in bladder cancer cells with different TP53 status.

Authors:  Daiane Teixeira DE Oliveira; Andre Luiz Ventura Savio; Joao Paulo DE Castro Marcondes; Tatiane Martins Barros; Ludmila Correia Barbosa; Daisy Maria Favero Salvadori; Glenda Nicioli DA Silva
Journal:  J Biosci       Date:  2017-03       Impact factor: 1.826

Review 3.  Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Authors:  Tomas Koltai; Larry Fliegel
Journal:  J Evid Based Integr Med       Date:  2022 Jan-Dec

Review 4.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

Review 5.  Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives.

Authors:  Peter F Surai
Journal:  Antioxidants (Basel)       Date:  2015-03-20

Review 6.  Broad targeting of angiogenesis for cancer prevention and therapy.

Authors:  Zongwei Wang; Charlotta Dabrosin; Xin Yin; Mark M Fuster; Alexandra Arreola; W Kimryn Rathmell; Daniele Generali; Ganji P Nagaraju; Bassel El-Rayes; Domenico Ribatti; Yi Charlie Chen; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Somaira Nowsheen; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; Bill Helferich; Xujuan Yang; Gunjan Guha; Dipita Bhakta; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Dorota Halicka; Sulma I Mohammed; Asfar S Azmi; Alan Bilsland; W Nicol Keith; Lasse D Jensen
Journal:  Semin Cancer Biol       Date:  2015-01-16       Impact factor: 15.707

7.  Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.

Authors:  Shan Guan; Yanling Zhao; Jiaxiong Lu; Yang Yu; Wenjing Sun; Xinfang Mao; Zhenghu Chen; Xin Xu; Jessie Pan; Surong Sun; Jianhua Yang
Journal:  Oncotarget       Date:  2016-11-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.